Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early-stage Hodgkin's disease.

A Josting1, V Diehl

  • 1First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany.

Current Oncology Reports
|April 11, 2001
PubMed
Summary

Treatment for early-stage Hodgkin's disease (HD) is evolving. Current approaches for favorable early-stage HD combine chemotherapy with involved-field irradiation, while unfavorable early-stage HD receives more intensive chemotherapy and irradiation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvement in the outcome of invasive fusariosis in the last decade.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2013
Same author

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same author

[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].

Der Pathologe·2005
Same author

BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.

Leukemia & lymphoma·2005
Same author

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).

Annals of oncology : official journal of the European Society for Medical Oncology·2005

Area of Science:

  • Oncology
  • Radiation Oncology
  • Clinical Medicine

Background:

  • Hodgkin's disease (HD) staging dictates treatment strategy.
  • Historically, early-stage HD (Stages I-IIIA) received different management than advanced stages.
  • Early-stage HD with risk factors indicated a worse prognosis, necessitating revised treatment protocols.

Purpose of the Study:

  • To outline the evolving treatment paradigms for early-stage Hodgkin's disease.
  • To differentiate management strategies based on risk stratification within early-stage HD.
  • To highlight the shift away from extended-field irradiation in favor of more targeted therapies.

Main Methods:

  • Review of historical and current treatment protocols for early-stage Hodgkin's disease.
  • Analysis of treatment outcomes based on disease stage and risk factors.
  • Comparison of extended-field irradiation with involved-field irradiation and chemotherapy combinations.

Main Results:

  • Extended-field (EF) irradiation, once standard, is being abandoned due to high relapse rates and long-term toxicity.
  • Favorable early-stage HD is now treated with mild chemotherapy and involved-field (IF) irradiation.
  • Early-stage unfavorable (intermediate) HD is managed with four cycles of chemotherapy plus IF irradiation.

Conclusions:

  • Treatment for early-stage Hodgkin's disease has significantly advanced.
  • Current strategies prioritize less toxic, more targeted approaches like involved-field irradiation combined with chemotherapy.
  • Risk stratification is crucial for tailoring effective Hodgkin's disease treatment.

Related Experiment Videos